Lancet Infectious Diseases

Article	Citations
Adaora “Ada” Alise Adimora	1547
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis	1371
Highlights from the sixth ESCMID Conference on Vaccines	1034
DNDi receives Dutch funding boost	685
HIV vaccine trial failure	586
Research in brief	583
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum	504
COVID-19 vaccination protects children and adolescents	419
Environment and infectious diseases	397
Promoting diversity and equity in publishing	374
A step forward in the journey towards hookworm vaccines	359
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7	332
Listeria monocytogenes: a rare, deadly cause of peritonitis	313
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations	301
Updated criteria for paediatric sepsis and septic shock	288
Infectious disease surveillance update	287
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges	281
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation	272
Surge of cutaneous leishmaniasis in Pakistan	268
Reflecting on lessons from the 2014–16 Ebola virus outbreak	267
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations	266
The next chapter for Africa's genomic initiatives	257
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic	242
The lasting lessons of mpox: infection, vaccination, and immune memory	229
Attention to skin-related neglected tropical diseases	216

Shaping opportunities for future clinical trials in tuberculosis	211
Ivan Hirsch	208
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting	195
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study	194
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study	194
Kyasanur Forest disease: an emerging arboviral threat	192
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1	191
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial	185
The superiority of bivalent over monovalent booster vaccines	183
Threat of HIV and tuberculosis drug resistance after US funding cuts	182
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children	177
Dihydroartemisinin–piperaquine versus chloroquine for the treatment of uncomplicated Plasmodium vivax malaria with concurrent or delayed high-dose primaquine in Brazil (Curavivax): an open-label, sing	167
A patient with secondary syphilis following incomplete treatment of primary infection	160
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C	158
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial	151
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria	149
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review	146
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial	146
Measles immunity gaps and outbreak risk in a shifting landscape	145
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom	144
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis	143
Best practice guidelines for viral hepatitis service delivery in prisons	142
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial	142
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study	141
GoGoVax dispels hopes for gonorrhoea vaccination	141
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden	141
Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer	140
Correction to Lancet Infect Dis 2025; 25: e280–93	138
Correction to Lancet Infect Dis 2020; 20: 60–79	138
New UN resolution links NTDs to human rights	136
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect	134
Mpox in people with past infection or a complete vaccination course: a global case series	132
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco	131
New flavours of tuberculosis treatment for children	127
Research in brief	127
Research in brief	127
A new monoclonal in the arMAMentarium against malaria	126
Global cholera resurgence—a preventable tragedy	124
The implications of mpox breakthrough infections on future vaccination strategies	122
Theresa Ochoa—staying on top of infectious diseases in Peru	119
Research in brief	117
RSV prevention: public health lessons from the southern hemisphere	115
Full-dose NSAIDs at the first sign of respiratory infection?	113
Tuberculosis recovery in Georgia: implementing more by 24	110
Election of Regional Director for the Western Pacific	109
Emil Gotschlich	109
Serpiginous-like choroiditis in ocular tuberculosis	107
Supporting healthcare access for refugees and migrants	107
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86	105
Infectious disease surveillance update	105

COVID-19 mortality in Africa and Asia – Authors' reply	104
High-dose primaquine reduces vivax relapses: time for change	104
Elisabeth Presterl—always looking forward	103
Research in brief	102
The response of mpox-associated inflammatory syndrome to steroid therapy	102
Immune evasiveness of SARS-CoV-2 variants and vaccine selection	101
Guidelines adherence as a major protective aspect to increase survival rate in patients with candidaemia in Europe	100
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa	100
Curing chronic hepatitis B virus infection	98
Addressing the shortage of cholera vaccines	98
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply	97
Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance	97
Patient-centred approaches for drug-resistant tuberculosis	97
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-0	96
Correction to Lancet Infect Dis 2023; 23: e469	95
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2	95
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5	93
Correction to Lancet Infect Dis 2025; 25: e47–58	91
Correction to Lancet Infect Dis 2025; 25: e622	89
Vaccine and surveillance implications of dengue underdetection	86
WHO Pathogen X conference	85
Malaria vaccine development in Mali: a step towards transmission-blocking strategies	85
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis	84
When mpox is not mpox: varicella and measles in DR Congo	82
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant	82
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	81
Correction to Lancet Infect Dis 2026; published online March 23. https://doi.org/10.1016/S1473-3099(26)00058-7	81
What can be learnt from the world's first national vaccination programme against gonorrhoea	81
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis	80
Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention	80
WHO publishes update on global antibiotic resistance	79
WHO's first global infection prevention and control report	78
Post-viral sequelae of COVID-19 and influenza	78
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia	78
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents	78
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-	77
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis	77
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?	77
Twin threats: climate change and zoonoses	76
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study	76
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study	76
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	75
Troy Grennan—getting anal cancer the attention it deserves	75
The global burden of cryptococcosis—a neglected tropical disease?	75
The Bundibugyo virus disease outbreak: a warning signal for risks to health workers	75
Infectious disease surveillance update	74
Spreading awareness on lymphatic filariasis	74
Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: a double-blind, randomised, placebo-controlled, phase 2b trial	74
Super-spreaders: a historical review	74
Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south	73
Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	73
Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study	73
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study	73
Correction to Lancet Infect Dis 2020; 20: 37–59	73
The spatiotemporal ecology of Oropouche virus across Latin America: a multidisciplinary, laboratory-based, modelling study	72
Lessons learnt from conducting a randomised clinical trial in eumycetoma	72
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial	72
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial	72
A step closer to elimination of meningococcal disease	72
Advancing integration: progress reported for skin NTDs	71
RH5.1/Matrix-M: highlighting blood-stage malaria vaccines	71
Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials	70
Outbreaks compound Brazil's flooding disaster	70
Statistical concerns for meta-analysis of rare events and small sample sizes – Authors' reply	70
Vaccine pragmatism in the 21st century	69
Pui-Ying Iroh Tam	69
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil	68
On the frontline during the COVID-19 pandemic	67
The urgent need to scale-up fungal diagnostics in Africa	67
Sir Michael Anthony Epstein	66
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices	66
Child-friendly rifapentine formulation is a game changer	65
Social workers and neglected tropical diseases	65
Imprinted hybrid immunity against XBB reinfection	65
Moxidectin versus ivermectin for strongyloidiasis control	65
Research in brief	64
Sleeping sickness: time for dreaming	64
Unexpected finding in a 17-year-old female undergoing screening colonoscopy	64
Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa	63
A tale of potential mpox reinfection	63

COVID-19 mortality in Africa and Asia	63
Human ocular thelaziosis—a zoonosis of the eye	63
Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7	63
Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluste	62
Correction to Lancet Infect Dis 2023; 23: e259–65	62
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial	61
Incidence and risk factors of tuberculosis among 420 854 household contacts of patients with tuberculosis in the 100 Million Brazilian Cohort (2004–18): a cohort study	61
Correction to Lancet Infect Dis 2023; published online Aug 3. https://doi.org/10.1016/S1473-3099(23)00344-4	61
DoxyPEP: thinking towards implementation	61
Re-emergence of Oropouche virus in Brazil and Latin America	60
Next-generation malaria subunit vaccines to reduce disease burden in African children	60
A rare case of rabies-like Australian bat lyssavirus infection	60
doxyPEP: a controversial new tool against STIs	60
Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch	59
Gender and geographical representation at infectious diseases and clinical microbiology conferences	59
Bangladesh launches measles vaccine drive amid outbreak	58
Effectiveness of pyriproxyfen-pyrethroid and chlorfenapyr-pyrethroid long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs for malaria control in the third year post-distribution:	58
Lassa fever research priorities: towards effective medical countermeasures by the end of the decade	58
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster	57
Can stochastic modelling predict cross-border spread of the Bundibugyo Ebola virus outbreak in Africa?	57
Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows	56
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis	56
Prevention of non-ventilator-associated hospital-acquired pneumonia in Switzerland: a type 2 hybrid effectiveness–implementation trial	56
Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study	56
National case series of group A streptococcus pleural empyema in children: clinical and microbiological features	56
A shared history	56
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3	56
Understanding the immunogenicity of RTS,S in infants	56
Learning and confirming in publicly funded antiviral trials	55
Randomised controlled trials for mpox in endemic countries	55
Experts react to SAGO's preliminary report	55
A step forward for Plasmodium falciparum malaria transmission-blocking vaccines	55
Monkeypox trial to begin in DR Congo	54
A vanquished threat or a cautionary tale?	54
Lyda Osorio—tackling South America's infectious diseases	54
Antiblackness in the Ebola response in Sierra Leone	53
Global measles cases up 20% in 2023	53
Deaths of unknown cause in DR Congo	53
Reporting of deaths during cholera outbreaks: case fatality ratio and community deaths	52
Hospital admissions for group A streptococcal infections in England: current rates and historical perspective	51
Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions	51
Lessons from the English primary care sentinel network's response to the COVID-19 pandemic	50
Correction to Lancet Infect Dis 2025; 25: e11–12	50
Developing the EAVE III platform for future health crises	50
Correction to Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S1473-3099(23)00731-4	50
Correction to Lancet Infect Dis 2023; 23: 789	50
Successful use of interferon alfa-2a for persistent parvovirus B19 infection	49
The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus	49
Correction to Lancet Infect Dis 2025; 25: 764–74	49
Candida albicans fungal ball in the eyeball	48
Mpox control strategies: using behaviour change to complement, not replace, vaccination	48
A new formulation of praziquantel to achieve schistosomiasis elimination	48
What is the pandemic potential of avian influenza A(H5N1)?	48
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomi	47
Correction to Lancet Infect Dis 2025; published online Oct 29. https://doi.org/10.1016/S1473-3099(25)00466-9	47
A new key-player for onchocerciasis elimination	47
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation	47
Na-GST-1 adsorbed on Alhydrogel co-administered with different Toll-like receptor agonists in hookworm-naive adults using a controlled human infection model in the USA: a phase 2, double-blind, random	46
Struggling with a new dengue epidemic in Nepal	46
Sabiha Essack—helping Africa lead the fight against AMR	46
Correction to Lancet Infect Dis 2025; published online Feb 13. https://doi.org/10.1016/S1473-3099(24)00749-7	46
Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021–22: a descriptive epidemiological study	46
Meningococcal disease, meningococcal vaccines, and the recent meningococcal outbreak in Kent, UK	46
Revisiting oral antivirals for COVID-19 in the hospital setting	46
A combined ELISA for infection-induced and vaccine-induced mpox antibodies during the clade Ib outbreak in Rwanda: an observational, cross-sectional, clinical validation study	45
H5N1 avian influenza: tracking outbreaks with real-time epidemiological data	45
Azithromycin mass drug administration: balancing survival benefits and risks in children	44
COVID-19 versus influenza: the need to align policies with COVID-19 realities	44
Measuring population immunity against influenza using individual antibody titres: a multicountry, retrospective observational study	44
Artificial intelligence to transform public health in Africa	44
Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis	44
Sense and susceptibility: predicting influenza dynamics from immune landscapes	44
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-base	44
Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia	44
Understanding vancomycin nephrotoxicity augmented by β-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and β-lactam chemistry	44
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African c	44
Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prosp	43
Mallika Imwong—championing malaria genomics	43
Safety, pharmacokinetics, and antimalarial efficacy of single-dose cabamiquine–pyronaridine combination therapy for the treatment of adults and adolescents with acute uncomplicated Plasmodium falcipar	43
Limited progress towards immunisation targets in 2023	43
Highlights from ASTMH 2024	43
Navigating treatment duration in osteoarticular Candida infections – Authors' reply	42
Correction to Lancet Infect Dis 2024; published online May 31. https://doi.org/10.1016/S1473-3099(24)00221-4	42
GLASS report on antibiotic use data for 2022	42
Infectious diseases in the COVID-19 era: gaps between countries	42
Ana Gligić	42
Real-world use of nirmatrelvir–ritonavir: who benefits?	42
Ophthalmic manifestation of monkeypox infection	41
Research in brief	41
Improving antimalarial therapeutic efficacy studies	41
The insights from SARS-CoV-2 antibody treatment for future emerging infectious diseases	41
Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy mala	41
Shorter treatment in chronic Chagas disease: a new promise?	41
Impact of the Global Fund Regional Artemisinin-resistance Initiative on malaria control and elimination in the Greater Mekong subregion of southeast Asia	40
A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab	40